Scholarlink

Objective <p>Homologous recombination (HR) status plays a pivotal role in the management of advanced ovarian cancers, particularly in guiding the use of PARP inhibitors. In patients receiving neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), tumor samples are available both before and after chemotherapy. This study evaluated the impact of NAC on HR status using paired pre- and post-NAC samples.</p> Methods <p>Between 2020 and 2023, 128 patients with ovarian cancer were treated at our institution; 24 underwent NAC followed by IDS. Genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status were assessed using the Myriad myChoice® assay. Paired analyses included cases with both pre- and post-NAC samples.</p> Results <p>Post-NAC HR assessment was unavailable in 8 of 24 patients (33%) due to insufficient or degraded tumor tissue. Paired HR status evaluation was therefore feasible in 15 patients. Among these paired evaluable cases, tBRCA mutation status remained unchanged. GIS scores significantly decreased in HR-deficient (HRD) tumors, whereas no significant change was observed in HR-proficient (HRP) tumors. The median ΔGIS was − 6, indicating a reduction after NAC. Two patients converted from HRD to HRP status after NAC, crossing the HRD threshold of 42.</p> Conclusions <p>Our findings suggest that NAC may reduce GIS and alter HR status in HRD tumors. Limited tissue availability after NAC poses a practical challenge for HR assessment, and HRD-to-HRP conversion may affect eligibility for HR-targeted therapies. These findings support performing HRD testing prior to chemotherapy whenever feasible.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月23日

查看全文
  • Akemi Morimoto,
  • Takashi Matsumoto,
  • Norifumi Teramoto,
  • Sakiko Murakami,
  • Tomoka Usami,
  • Junko Murai,
  • Takashi Sugiyama

摘要

Objective

Homologous recombination (HR) status plays a pivotal role in the management of advanced ovarian cancers, particularly in guiding the use of PARP inhibitors. In patients receiving neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), tumor samples are available both before and after chemotherapy. This study evaluated the impact of NAC on HR status using paired pre- and post-NAC samples.

Methods

Between 2020 and 2023, 128 patients with ovarian cancer were treated at our institution; 24 underwent NAC followed by IDS. Genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status were assessed using the Myriad myChoice® assay. Paired analyses included cases with both pre- and post-NAC samples.

Results

Post-NAC HR assessment was unavailable in 8 of 24 patients (33%) due to insufficient or degraded tumor tissue. Paired HR status evaluation was therefore feasible in 15 patients. Among these paired evaluable cases, tBRCA mutation status remained unchanged. GIS scores significantly decreased in HR-deficient (HRD) tumors, whereas no significant change was observed in HR-proficient (HRP) tumors. The median ΔGIS was − 6, indicating a reduction after NAC. Two patients converted from HRD to HRP status after NAC, crossing the HRD threshold of 42.

Conclusions

Our findings suggest that NAC may reduce GIS and alter HR status in HRD tumors. Limited tissue availability after NAC poses a practical challenge for HR assessment, and HRD-to-HRP conversion may affect eligibility for HR-targeted therapies. These findings support performing HRD testing prior to chemotherapy whenever feasible.